Fournier's gangrene is a rare and severe complication reported in patients with cancer treated with antiangiogenic drugs, most frequently with bevacizumab. The present report describes the case of an 80-year-old man with radioactive iodine-refractory metastatic thyroid cancer treated with lenvatinib (an oral multikinase inhibitor with antiangiogenic properties) who developed Fournier's gangrene in the absence of other known risk factors. To the best of our knowledge, this is the first case described during treatment with lenvatinib. The condition was likely due to a perturbation of vascular endothelial cells of the skin due to the inhibition of VEGF/VEGFR signaling. Fournier's gangrene may be a class effect of antiangiogenic treatment that clinicians should be aware of, as early diagnosis and treatment are associated with an improved outcome.
CITATION STYLE
Barone, M., Grani, G., Ramundo, V., Garritano, T., Durante, C., & Falcone, R. (2020). Fournier’s gangrene during lenvatinib treatment: A case report. Molecular and Clinical Oncology, 12(6), 588–591. https://doi.org/10.3892/mco.2020.2031
Mendeley helps you to discover research relevant for your work.